AzTrials
AzTrials

Bladder CancerNCT06688643

The Impact of Intrathecal Morphine Versus Continuous Epidural Analgesia on Return of Bowel Function in Patients Undergoing Laparoscopic Ileal Conduit

A study testing ITM group and EA group in people with Bladder Cancer, run by Xiaguang Duan at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to compare the effects of intrathecal morphine (ITM) and continuous epidural analgesia (CEA) on bowel function recovery after Bricker surgery.This study was a prospective, randomized controlled trial that included 72 patients with bladder cancer undergoing elective Bricker surgery, who were randomly… Read more about this study

Who is it for?
Any age
Conditions the study is for
Bladder Cancer
What is being tested?
ITM group and EA group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
58 participants
Where
1 siteChina
Study dates
25 Jan 2022to 1 Nov 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • All participants provided informed consent voluntarily
  • ASA I-III

Who cannot join

  • allergies to any anesthetic agents used in this study
  • refused to sign the consent form
  • uncooperative were deemed ineligible for clinical evaluation
  • hypersensitivity to pain
  • a history of gastrointestinal disease
  • sleep disorders

Trial locations and contacts

1 site in 1 country.

China1 site
  • Inner Mongolia Baogang Hospital

    Baotou, Inner Mongolia, 014010

Other trials in China

About this study

Official title: The Impact of Intrathecal Morphine Versus Continuous Epidural Analgesia on Return of Bowel Function in Patients Undergoing Laparoscopic Ileal Conduit : a Prospective, Randomized Controlled Trial

This study aims to compare the effects of intrathecal morphine (ITM) and continuous epidural analgesia (CEA) on bowel function recovery after Bricker surgery.This study was a prospective, randomized controlled trial that included 72 patients with bladder cancer undergoing elective Bricker surgery, who were randomly assigned to either the ITM group (n=36) or the CEA group (n=36). Postoperatively, patients in both groups received either ITM or CEA for pain management, and postoperative bowel function recovery time, pain scores, PONV, itching, and other indicators were recorded.

Read the detailed description

Patients This study was approved by the Medical Ethics Committee of Baogang Hospital, Inner Mongolia (2021-MER-206) on October 11, 2021, and adhered to the Declaration of Helsinki and the Consolidated Standards of Reporting Trials (CONSORT) guidelines. All participants provided informed consent voluntarily. From January 25, 2022, to November 1, 2024, 72 patients (aged 50-90 years) with bladder cancer undergoing elective Bricker surgery were enrolled at Baogang Hospital, Inner Mongolia. All patients were classified as ASA I-III. Patients were excluded if they had allergies to any anesthetic agents used in this study or if they had adverse reactions to any of the analgesics included in the study. Patients who refused to sign the consent form or were uncooperative were deemed ineligible for clinical evaluation. Patients were excluded if they had uncontrolled hypertension, hypersensitivity to pain, a history of gastrointestinal disease, impaired cardiopulmonary function, cerebrovascular disease, sleep disorders, or psychiatric disorders.

Randomization and blinding Patients were randomly assigned to the ITM group (n=36) or EA group (n=36) using a random number table. Patients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room. Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine. General anesthesia with endotracheal intubation was administered to both groups after the aforementioned procedures. Patients and surgeons were blinded to group assignment, while the anesthesiologists and nurses administering anesthesia were aware of the group allocation.

General anesthesia and monitoring Upon arrival in the operating room, patients were monitored for pulse oximetry (SPO2), electrocardiogram (ECG), bispectral index (BIS), and non-invasive arterial blood pressure. Pain threshold (PTh, mA) and pain tolerance threshold (PTTh, mA) were measured and recorded. Patients received pre-operative administration of Penehyclidine Hydrochloride Injection (Lot H20051948, Chengdu List Pharmaceutical Co., Ltd., China) (0.01 mg kg-1 i.v.). Induction was achieved with propofol (1.5-2 mg kg-1 i.v.), rocuronium bromide (1-2 mg kg-1 i.v.), and fentanyl (1-2 μg kg-1 i.v.). Anesthesia was maintained with inhaled sevoflurane or desflurane, with the inhaled concentration adjusted according to BIS values. Remifentanil (0.05-0.2 μg kg-1 min-1 i.v.) was continuously infused to maintain blood pressure and heart rate within ±20% of baseline values. Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%. The patient was positioned in the Trendelenburg position, with the operating table tilted 20-25° head down. Carbon dioxide pneumoperitoneum was established at an intra-abdominal pressure of 10-15 mmHg.

Postoperative care Vital signs were monitored in the Post Anesthesia Care Unit (PACU), with supplemental oxygen provided via facemask. For hypotension, ephedrine (6-10 mg) was administered, and fluid administration was increased. Atropine (0.3-0.5 mg) was given for bradycardia. For pain, sufentanil (0.1-0.2 μg/kg) was administered.

Data collection Upon arrival in the operating room, HR (bpm), mean arterial pressure (MAP, mmHg) (calculated as MAP = diastolic pressure + 1/3 pulse pressure), BIS, remifentanil dosage (mg), ephedrine dosage (mg), duration of surgery (minutes), and duration of anesthesia (minutes) were recorded for all patients.

In the PACU, the following data were recorded: number of patients requiring sufentanil (μg), number of patients experiencing respiratory depression (n), number of hypotension events requiring intervention (n), ephedrine dosage (mg), intravenous fluid volume (ml), number of patients experiencing bradycardia (n), atropine dosage (mg), Bromage score, and time spent in the PACU (min). For patients transferred to the high dependency unit, the number of patients (n) and length of stay (h) were recorded.

Postoperatively, rest pain (Numerical Rating Scale, NRS), dynamic pain (NRS), morphine equivalent (mg), quality of sleep on the first night (Likert scale, 1-5), functional recovery (return of bowel function, h, recommencement of oral intake, h, and time to first mobilization, h), quality of recovery (QoR, 0-15) on postoperative day 1, and hospital stay (days) were recorded at 4, 8, 12, and 24 hours. Ketorolac dosage (mg), hydromorphone dosage (mg), oral medications, number of episodes of PONV (n), antiemetic dosage (mg), number of episodes of pruritus (n), and Comprehensive Complication Index (CCI) were recorded over 24 hours.

Statistical analysis Sample size estimation was conducted using PASS 21.0.3 software (NCSS, LLC, Kaysville, Utah, USA), selecting the "Two-Sample T-Tests Allowing Unequal Variance" module10,11. With sample sizes of 23 in each group, a two-sided, two-sample t-test with unequal variances achieves 91.25% power to reject the null hypothesis of equal means at a significance level (alpha) of 0.05.The calculated results indicated an average group sample size (n) of 23, a 20% dropout rate, and a dropout-inflated expected enrollment sample size of 29.

Data were presented as means (standard deviations), frequencies (%), or medians (Confidence Interval). All statistical analyses were conducted using GraphPad Prism software version 10.2.3. The Kolmogorov-Smirnov test was performed to investigate the normality of the distribution of continuous variables. An independent t test or Mann-Whitney U test was performed to compare continuous variables, as appropriate. The x2 test or Fisher's exact was performed to compare categorical variables. Repeated-measures analysis of variance was performed to compare changes in some variables over time. Statistical significance was set at P value <0.05.

Conditions
Bladder Cancer
Being tested
ITM group, EA group
Keywords
Bowel function, Continuous epidural analgesia (CEA), intrathecal morphine(ITM), laparoscopic ileal conduit (Bricker), Postoperative nausea and vomiting(PONV), Pruritus
Medical subject headings
Urinary Bladder Neoplasms, Postoperative Nausea and Vomiting, Pruritus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ITM groupDevice

    Patients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.

  • EA groupDevice

    Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.

Study groups in NCT06688643
Study groupRoleWhat they receive
ITM groupExperimentalPatients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room.
Receives: Device: ITM group
EA groupExperimentalPatients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.
Receives: Device: EA group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. bowel function recovery time

    12 hours indicates good bowel function, 24 hours indicates good bowel function.

    Measured: 24 hours after surgery

Secondary outcomes (1)
  1. pain scores

    Zero is equivalent to no pain and 10 indicates the worst possible pain.

    Measured: 24 hours after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Nov 2024
  2. Study start25 Jan 2022
  3. Primary completion1 Nov 2024
  4. Study completion1 Nov 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
58 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06688643
Sponsor's protocol ID
2021-MER-206
Status last verified
Oct 2021
First submitted
11 Nov 2024
Last updated
14 Nov 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: all IPD that underlie results in a publication

Questions about this trial

What is this clinical trial studying?

A study testing ITM group and EA group in people with Bladder Cancer, run by Xiaguang Duan at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

bowel function recovery time (time frame: 24 hours after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in